Abstract: In a nonaqueous electrolyte secondary battery having a positive electrode containing a positive electrode active material, a negative electrode containing a negative electrode active material, and a nonaqueous electrolyte, as the positive electrode active material or as the negative electrode active material, a mixture containing molybdenum dioxide and lithium titanate in a weight ratio (molybdenum dioxide:lithium titanate) of 90:10 to 50:50 is used.

Abstract: A non-aqueous electrolyte secondary battery includes a positive electrode (1) containing lithium cobalt oxide as a positive electrode active material, a negative electrode (2) containing molybdenum dioxide as a negative electrode active material, and a non-aqueous electrolyte. The mass ratio of the negative electrode active material to the positive electrode active material is within the range of from 0.725 to 0.480. The conductive agent of the negative electrode consists of a carbon material having a lattice constant C0 along a stacking direction of from 6.7 ? to 6.8 ?, as determined by X-ray diffraction, or the negative electrode contains no conductive agent made of carbon material.

Abstract: In a nonaqueous electrolyte secondary battery having a positive electrode containing a positive electrode active material, a negative electrode containing a negative electrode active material, and a nonaqueous electrolyte, as the positive electrode active material or as the negative electrode active material, a mixture containing molybdenum dioxide and lithium titanate in a weight ratio (molybdenum dioxide:lithium titanate) of 90:10 to 50:50 is used.

Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent. The present invention relates to an antibacterial aqueous pharmaceutical composition which comprises: 2.8 to 4 w/v % of methylcellulose, the 2 w/v % aqueous solution of which has a viscosity of 12 mPa·s or below at 20° C.; 1.5 to 2.3 w/v % of citric acid; 2 to 4 w/v % of polyethylene glycol; and 0.1 to 0.5 w/v % of ofloxacin.

Abstract: An object is to provide a control apparatus of a showcase in which appropriate illumination having a high presentation effect can be realized by an LED illumination apparatus having a high durability against turning ON/OFF and capable of securing a predetermined illumination intensity even under an environment at a low temperature. The control apparatus controls a plurality of showcases so that display chambers where commodities are displayed are illuminated with LED illumination apparatuses, and includes a person detecting sensor provided in a showcase disposed in such a position that the approaching of any person can first be detected among the plurality of arranged showcases, so that the approaching of the person is detected. When the person detecting sensor detects the approaching of the person, the illumination intensities of all the LED illumination apparatuses of the plurality of showcases are increased.

Abstract: Disclosed are an active material for non-aqueous electrolyte secondary battery usable as a power source for backup, which has a large battery capacity and which may prevent the increase in the internal resistance after a storage test; and a non-aqueous electrolyte secondary battery comprising the active material. The active material is used as a positive electrode active material or a negative electrode active material of a non-aqueous electrolyte secondary battery, and this is prepared by adding at least one additive element selected from a group consisting of Al, B, Nb, Ti and W to molybdenum dioxide; and the non-aqueous electrolyte secondary battery comprises the active material.

Abstract: A lithium secondary battery including a positive electrode, a negative electrode, a separator, and a nonaqueous electrolyte including a solute and a solvent, wherein the separator is made of glass fibers and the negative electrode includes a lithium-aluminum-manganese alloy as an active material.

Abstract: A nonaqueous electrolyte secondary battery including a positive electrode containing a positive active material, a negative electrode containing a negative active material and a nonaqueous electrolyte. The secondary battery contains, as the negative active material, a lithium-containing molybdenum oxide represented by a chemical formula LixMoO2 (0.05?x?0.25) when in a fully discharged state. The lithium-containing molybdenum oxide can be obtained by allowing lithium to react to molybdenum dioxide (MoO2) electrochemically, for example.

Abstract: In a nonaqueous electrolyte secondary battery having a positive electrode containing a positive electrode active material, a negative electrode containing a negative electrode active material, and a nonaqueous electrolyte, as the positive electrode active material or as the negative electrode active material, a mixture containing molybdenum dioxide and lithium titanate in a weight ratio (molybdenum dioxide:lithium titanate) of 90:10 to 50:50 is used.

Abstract: A nonaqueous electrolyte secondary battery including positive and negative electrodes capable of occluding and releasing lithium and a nonaqueous electrolyte and in which the negative electrode includes a foamed metal containing silicon as an active material therein.

Abstract: A non-aqueous electrolyte secondary battery includes a positive electrode (1) containing lithium cobalt oxide as a positive electrode active material, a negative electrode (2) containing molybdenum dioxide as a negative electrode active material, and a non-aqueous electrolyte. The mass ratio of the negative electrode active material to the positive electrode active material is within the range of from 0.725 to 0.480. The conductive agent of the negative electrode consists of a carbon material having a lattice constant C0 along a stacking direction of from 6.7 ? to 6.8 ?, as determined by X-ray diffraction, or the negative electrode contains no conductive agent made of carbon material.

Abstract: The present invention provides an ophthalmic aqueous pharmaceutical preparation, which is excellent in anti-inflammatory effect, which is less stimulative and which has high safety and excellent storage stability. The ophthalmic aqueous pharmaceutical preparation comprises meloxicam and trometamol.

Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent. The present invention relates to an antibacterial aqueous pharmaceutical composition which comprises: 2.8 to 4 w/v % of methylcellulose, the 2 w/v % aqueous solution of which has a viscosity of 12 mPa·s or below at 20° C.; 1.5 to 2.3 w/v % of citric acid; 2 to 4 w/v % of polyethylene glycol; and 0.1 to 0.5 w/v % of ofloxacin.

Abstract: A non-aqueous electrolyte secondary battery includes a positive electrode, a negative electrode, and a non-aqueous electrolyte, and the negative electrode contains a conductive agent and a negative electrode active material including a lithium titanium oxide. The conductive agent in the negative electrode includes graphitized vapor grown carbon fiber having a lattice constant C0 along a stacking direction of from 6.7 ? to 6.8 ?, as determined by X-ray diffraction.

Abstract: A lithium secondary battery including a positive electrode, a negative electrode which is a lithium-aluminum alloy, a separator of a glass fiber including SiO2, B2O3 and Na2O, and a nonaqueous electrolyte including a solute and a solvent. The lithium secondary battery has excellent battery characteristics after a reflow treatment.

Abstract: A lithium secondary battery including a positive electrode, a negative electrode, a separator, and a nonaqueous electrolyte including a solute and a solvent, wherein the separator is made of glass fibers and the negative electrode includes a lithium-aluminum-manganese alloy as an active material.

Abstract: A nonaqueous electrolyte secondary battery including positive and negative electrodes capable of occluding and releasing lithium and a nonaqueous electrolyte and in which the negative electrode includes a foamed metal containing silicon as an active material therein.

Abstract: A lithium secondary battery including a positive electrode, a negative electrode and a nonaqueous electrolyte containing a solute dissolved in a nonaqueous solvent, wherein a lithium-aluminum-manganese alloy in which lithium is occluded in an aluminum-manganese alloy is a material of the negative electrode, and the nonaqueous electrolyte contains a mixed solvent of a cyclic carbonate and a polyethylene glycol dialkyl ether as the nonaqueous solvent.

Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent.

Abstract: The present invention provides an ophthalmic aqueous pharmaceutical preparation, which is excellent in anti-inflammatory effect, which is less stimulative and which has high safety and excellent storage stability. The ophthalmic aqueous pharmaceutical preparation comprises meloxicam and trometamol.